Welcome to our dedicated page for Dss news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on Dss stock.
DSS, Inc. (NYSE American: DSS) generates news across a wide range of sectors, reflecting its role as a multinational company with diversified business lines in packaging, biohealth innovation, financial services, alternative trading, and real estate. The company’s press releases and regulatory disclosures highlight strategic transactions, capital markets developments, operational milestones, and portfolio optimization efforts.
News about DSS often covers corporate strategy and portfolio management, including spin-offs, asset sales, and transactions involving key subsidiaries. Examples include the sale of the Celios air purification asset to Impact BioMedical Inc., as well as a definitive merger agreement under which Impact BioMedical will be acquired through a reverse merger with Dr. Ashleys Limited, resulting in a new public company. These items illustrate DSS’s stated approach of unlocking value by advancing subsidiaries toward independent public listings and other exit opportunities.
Investors and followers of DSS can also expect updates on financial performance and corporate actions. The company reports on revenue trends, cash flow improvements, debt reduction, and asset monetization, such as the sale of a real estate facility and growth in rental income. Leadership communications, including letters to shareholders and announcements of executive appointments, provide additional context on strategic priorities, cost reduction initiatives, and the focus on core growth verticals.
Because DSS has subsidiaries in securities and investment management, its news flow includes developments at entities like Sentinel Brokers Company, Inc. and AmericaFirst Funds. These updates may involve regulatory approvals, such as FINRA authorization for underwriting activities, changes to mutual fund boards, and expansion of capital markets capabilities. For a comprehensive view of DSS-related developments, readers can use this news page to follow corporate strategy, subsidiary activity, and key financial and regulatory events over time.
Document Security Systems, Inc. (DSS) has announced a three-year, $6 million annual contract with a major retailer through its subsidiary, Premier Packaging Corp. The contract covers the supply of photo mailing envelopes and cartons and may extend to a fourth year, potentially totaling over $24 million. This deal underlines Premier's growth potential and effectiveness, fueled by recent investments in manufacturing and quality improvements. Production is set to start in Q3 2020, with the retailer planning to open 550 new stores, which could further enhance contract value.
Document Security Systems (DSS) announced the full exercise of an over-allotment option by the underwriter for its public offering, resulting in an additional 154,320 common shares sold at $6.25 each. The total gross proceeds from this offering will now amount to approximately $7.39 million. DSS plans to utilize the net proceeds for funding the development of new business lines, acquisitions, corporate needs, and working capital. Aegis Capital Corp. acted as the sole bookrunner for this offering.
On July 10, 2020, Document Security Systems (DSS) announced that Crecom Burj Group (CBG), a Malaysian PPE exporter, has adopted its AuthentiGuard as a Service (AGaaS) anti-counterfeiting technology. AGaaS helps verify product authenticity through a multi-layered marking system. This collaboration aims to ensure the integrity of CBG's AAMI-certified isolation gowns and gloves for the US healthcare market. Counterfeiting in global trade is rising, estimated at 3.3%, with losses projected to exceed $1.8 trillion by 2020. This partnership allows rapid implementation of integrity solutions across various industries.
Document Security Systems (DSS) has announced promising in-vitro testing results from its acquisition target, Impact Biomedical, focusing on COVID-19 treatments. The proprietary compounds, Equivir and Linebacker, showed effectiveness in blocking SARS-CoV-2 infection, while 3F Biofragrance functioned as a potent disinfectant. Impact Biomedical's antiviral suite has been valued at $933 million, exceeding previous estimates. The acquisition, set for $50 million in stock, positions DSS to leverage advanced biomedical technologies amid the ongoing pandemic.
Document Security Systems (NYSE American: DSS) announced the completion of a public offering of 1,028,800 shares at $6.25 each, raising approximately $6.43 million before expenses. The raised funds are earmarked for expanding new business lines, acquisitions, and general corporate purposes. Additionally, an underwriter has a 45-day option to purchase up to 154,320 additional shares. The offering was conducted under an effective shelf registration with the SEC, aiming to enhance growth and operational capabilities.
Document Security Systems has priced an underwritten public offering of 1,028,800 shares of common stock at $6.25 per share, generating gross proceeds of $6.43 million before expenses. The funds will support the growth of new business lines, acquisitions, and general corporate needs. Aegis Capital Corp. is managing the offering, expected to close on July 7, 2020. The underwriter has a 45-day option to purchase an additional 154,320 shares to cover over-allotments.
Document Security Systems (DSS) announced the full exercise of the underwriter's over-allotment option for its public offering, resulting in an additional 115,384 shares sold at $7.80 each. This increases total gross proceeds to approximately $6.9 million. The company plans to use these funds for business development, acquisitions, and closing unprofitable operations. The offering was made under an effective registration statement filed with the SEC.
Document Security Systems (DSS) has completed an underwritten public offering, raising $6.0 million through the sale of 769,230 shares at $7.80 per share. The company plans to allocate the net proceeds towards developing new business lines, acquisition opportunities, and covering operational costs associated with unprofitable ventures. Additionally, underwriters have a 45-day option to purchase up to 15% more shares. The offering follows an effective registration statement filed with the SEC.
Summary not available.